Top

BMC Infectious Diseases

Published in:

Open Access 01-12-2023 | Tuberculosis | Research

Interferon-γ release assay and mantoux response in infants with tuberculous meningitis in low and intermediate burden countries

Authors: Yan-Hua Yang, Jie Hou, Yu He, Yan-An Zhang, Mao-Shui Wang

Published in: BMC Infectious Diseases | Issue 1/2023

Abstract

Aim

Until now, the performance of interferon-γ release assay (IGRA) and Mantoux tests remains unclear in infant tuberculous meningitis (TBM). Therefore, a systematic review is performed to evaluate the sensitivity of IGRA and Mantoux tests for the diagnosis of infant TBM in low and intermediate tuberculosis (TB) burden countries, while following PRISMA.

Methods

Several databases, including PubMed, EBSCO, Embase, Scopus, Web of Science, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials, were searched. Articles describing the results of IGRA or Mantoux tests among infant TBM were included for analysis. Data, such as age, sex, Mantoux test or IGRA, and cerebrospinal fluid (CSF) microbiological examinations (such as acid-fast bacilli (AFB) smear, TB PCR, and TB culture), were extracted from each study.

Results

A total of 31 articles were enrolled for further analysis, including 48 cases. The mean age was 9.4 ± 5.8 months and boys accounted for 57.1% of infants (24/42). Mantoux test was positive in 57.4% (27/47) of tested infants and IGRA was positive in 77.8% (7/9) of infants. In addition, among the infants with confirmed TB, 18 (52.9%, 18/34) of them have positive Mantoux responses and 7 (20.0%, 7/35) have positive IGRA results.

Conclusions

In low or intermediate TB burden countries, the Mantoux test has a poor performance for diagnosing TBM among infants, and IGRAs appear to have a moderate sensitivity for the diagnosis of infant TBM.

Available only for authorised users

WHO. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.

Wang MS, Wang JL, Liu XJ. Epidemiological Trends in the form of Childhood Tuberculosis in a Referral Tuberculosis Hospital in Shandong, China. Biomed Res Int. 2020;2020:6142567. https://doi.org/10.1155/2020/6142567.CrossRefPubMedPubMedCentral

Chiang SS, Khan FA, Milstein MB, Tolman AW, Benedetti A, Starke JR, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(10):947–57. https://doi.org/10.1016/s1473-3099(14)70852-7.CrossRefPubMed

Chaya S, Dangor Z, Solomon F, Nzenze SA, Izu A, Madhi SA. Incidence of tuberculosis meningitis in a high HIV prevalence setting: time-series analysis from 2006 to 2011. Int J Tuberc Lung Dis. 2016;20(11):1457–62. https://doi.org/10.5588/ijtld.15.0845.CrossRefPubMed

Seddon JA, Tugume L, Solomons R, Prasad K, Bahr NC, Tuberculous Meningitis International Research C. The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res. 2019;4:167. https://doi.org/10.12688/wellcomeopenres.15535.1.CrossRefPubMedPubMedCentral

Li RL, Wang JL, Wang XF, Wang MS. Tuberculosis in infants: a retrospective study in China. Springerplus. 2016;5:546. https://doi.org/10.1186/s40064-016-2184-7.CrossRefPubMedPubMedCentral

Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10(11):803–12. https://doi.org/10.1016/S1473-3099(10)70138-9.CrossRefPubMed

Wang MS, Liu XJ. Risk factors for false-negative Interferon-gamma release assay results in culture-confirmed childhood TB. Am J Trop Med Hyg. 2019;101(6):1303–7. https://doi.org/10.4269/ajtmh.18-0684.CrossRefPubMedPubMedCentral

Basu Roy R, Sotgiu G, Altet-Gomez N, Tsolia M, Ruga E, Velizarova S, et al. Identifying predictors of interferon-gamma release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study. Am J Respir Crit Care Med. 2012;186(4):378–84. https://doi.org/10.1164/rccm.201201-0026OC.CrossRefPubMed

10.

Bang ND, Caws M, Truc TT, Duong TN, Dung NH, Ha DTM, et al. Clinical presentations, diagnosis, mortality and prognostic markers of tuberculous meningitis in vietnamese children: a prospective descriptive study. BMC Infect Dis. 2016;16(1):573. https://doi.org/10.1186/s12879-016-1923-2.CrossRefPubMedPubMedCentral

11.

Sun L, Xiao J, Miao Q, Feng WX, Wu XR, Yin QQ, et al. Interferon gamma release assay in diagnosis of pediatric tuberculosis: a meta-analysis. FEMS Immunol Med Microbiol. 2011;63(2):165–73. https://doi.org/10.1111/j.1574-695X.2011.00838.x.CrossRefPubMed

12.

Duque-Silva A, Robsky K, Flood J, Barry PM. Risk factors for Central Nervous System Tuberculosis. Pediatrics. 2015;136(5):e1276–84. https://doi.org/10.1542/peds.2014-3958.CrossRefPubMed

13.

Kimerling ME, Vaughn ES, Dunlap NE. Childhood tuberculosis in Alabama: epidemiology of disease and indicators of program effectiveness, 1983 to 1993. Pediatr Infect Dis J. 1995;14(8):678–84.CrossRefPubMed

14.

Murtagh K. Unreliability of the Mantoux test using 1 TU PPD in excluding childhood tuberculosis in Papua New Guinea. Arch Dis Child. 1980;55(10):795–9. https://doi.org/10.1136/adc.55.10.795.CrossRefPubMedPubMedCentral

15.

Shah I, Kathwate J, Shetty NS. Comparison of tuberculin skin test and QuantiFERON-TB gold In-Tube test in Bacillus Calmette-Guerin-vaccinated children. Lung India. 2020;37(1):24–9. https://doi.org/10.4103/lungindia.lungindia_304_19.CrossRefPubMed

16.

Debord C, De Lauzanne A, Gourgouillon N, Guerin-El Khourouj V, Pedron B, Gaudelus J, et al. Interferon-gamma release assay performance for diagnosing tuberculosis disease in 0- to 5-year-old children. Pediatr Infect Dis J. 2011;30(11):995–7. https://doi.org/10.1097/INF.0b013e3182272227.CrossRefPubMed

17.

Lombardi G, Pellegrino MT, Denicolo A, Corsini I, Tadolini M, Bergamini BM, et al. QuantiFERON-TB performs better in children, including infants, than in adults with active tuberculosis: a Multicenter Study. J Clin Microbiol. 2019;57(10). https://doi.org/10.1128/JCM.01048-19.

18.

Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, et al. Updated guidelines for using Interferon Gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010;59(RR–5):1–25.PubMed

19.

Lee YM, Park KH, Kim SM, Park SJ, Lee SO, Choi SH, et al. Risk factors for false-negative results of T-SPOT.TB and tuberculin skin test in extrapulmonary tuberculosis. Infection. 2013;41(6):1089–95. https://doi.org/10.1007/s15010-013-0478-z.CrossRefPubMed

20.

Di L, Li Y. The risk factor of false-negative and false-positive for T-SPOT.TB in active tuberculosis. J Clin Lab Anal. 2018;32(2). https://doi.org/10.1002/jcla.22273.

21.

Shaikh N, Gupte A, Dharmshale S, Pokkali S, Thakar M, Upadhye VJ, et al. Novel interferon-gamma assays for diagnosing tuberculosis in young children in India. Int J Tuberc Lung Dis. 2017;21(4):412–9. https://doi.org/10.5588/ijtld.16.0428.CrossRefPubMed

22.

Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, Meacci M, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006;367(9519):1328–34. https://doi.org/10.1016/S0140-6736(06)68579-6.CrossRefPubMed

23.

Seddon JA, Paton J, Nademi Z, Keane D, Williams B, Williams A, et al. The impact of BCG vaccination on tuberculin skin test responses in children is age dependent: evidence to be considered when screening children for tuberculosis infection. Thorax. 2016;71(10):932–9. https://doi.org/10.1136/thoraxjnl-2015-207687.CrossRefPubMed

Title: Interferon-γ release assay and mantoux response in infants with tuberculous meningitis in low and intermediate burden countries
Authors: Yan-Hua Yang
Jie Hou
Yu He
Yan-An Zhang
Mao-Shui Wang
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Tuberculosis
Tuberculosis
Meningitis
Interferon
Published in: BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-023-08327-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

The first case of Escherichia fergusonii with biofilm in China and literature review

Disseminated Mycobacterium thermoresistibile Infection presented with Lymphadenectasis in an AIDS patient: case report and review of literature

Disease burden of tuberculosis and post-tuberculosis in Inner Mongolia, China, 2016–2018 — based on the disease burden of post-TB caused by COPD

Comparative study of biomarkers for the early identification of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in infectious mononucleosis

The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis

A scoping review of media campaign strategies used to reach populations living with or at high risk for Hepatitis C in high income countries to inform future national campaigns in the United Kingdom

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials